| |
Patients (n=12) |
| Age, years, median (range) |
68.5 (56-78) |
| Sex (male/female), n (%) |
3/9 (25/75%) |
| Diagnosis, n (%) AML |
6 (50%) |
| MDS overt AML |
6 (50%) |
| Weight, Kg, median (range) |
48.2 (35.0-63.8) |
| Height, cm, median (range) |
150.1 (137.0-171.2) |
| BSA, m², median (range) |
1.46 (1.15-1.72) |
Chemotherapy at platelet transfusion refractoriness,
Idarubicin+Ara-C/CAG/HD-AraC, n (%) |
3/5/4(25/42/33%) |
| No. of units previously transfused, median (range) RBC |
24 (6-132) |
| (random donor units) Platelets |
155 (50-340) |
| Time to detection of anti-HLA Abs, months, median (range) |
4 (1-28) |
| HLA-matched platelets |
|
| No. of transfusions, median (range) |
10.5 (2-30) |
| No. of units, median (range) |
177.5 (25-490) |
| Platelet count (x1011)/no. of transfusions, median (range) |
3.2 (2.4-3.9) |
| No. of platelet units/no. of transfusions, median (range) |
16.2 (12.1-19.6) |
| ABO compatibility status/no. of patients (%) |
|
| ABO identical, median (range) |
37.5% (0-84) |
| ABO minor incompatible, median (range) |
10.2% (0-40) |
| ABO major incompatible, median (range) |
46.7% (0-100) |
